About genetic testing:


All currently known genetic mutations which indicate the risk of developing various types of cancer can be detected in one test after a standard blood sampling.

Every person is born with many different genetic mutations. Most of them do not negatively impact the quality of our lives. However, some of them increase the risk of cancers. Inherited and congenital mutations in the genes cause every one in four cancers.

That is why genetic testing is particularly recommended to people with family history of cancer. All genes related to a given cancer, e.g. the 25 genes which affect development of breast cancer, are analysed in one test.

 

A genetic test includes medical interpretation of test results carried out by a geneticist.

An analysis of the collected genetic material and interpretation of test results is carried out in the laboratory of Warsaw Genomics, a PETRA MEDICA partner. During a visit at the Medical Centre, the doctor discusses the identified mutations (if any were identified) and their impact on the risk of developing a specific cancer type in the future. Depending on the test results obtained,

age and gender, the patient receives detailed recommendations for individual prevention measures – how, when and how frequently should the patient monitor his/her health condition. This maximally reduces the risk of developing the disease, and should the disease actually develop, it can be detected at the earliest possible stage and effective treatment can be initiated.

Types of genetic tests


Our genetic tests cover 11 panels for different types of cancer, including the most prevalent ones: cancer of the colon, breast and ovaries, prostate, as well as skin, pancreas, stomach, thyroid and others.

Test method


The genetic test uses full genome sequencing carried out with the innovative massive parallel next-generation-sequencing method, which makes it possible to precisely determine the genetic burden which might result in the development of cancer.
We focus on isolated genes which, if mutated, increase the statistical risk of specific cancers (see the test panel list).

The value of result reinterpretation


Genetics and medicine are constantly evolving. That is why patients performing genetic tests in the Petra Medica Medical Centre are offered a reinterpretation of the results in relation to the latest discoveries of global science within 12 to 24 months after the test was performed (depending on the attending physician’s recommendation) – this allows for connecting detected mutations with newly discovered disease entities.

 

 

Material
for testing


A small amount of sampled blood (up to 10 ml) is sufficient to perform a test.

Results
of genetic tests


A description of the test results is prepared by an interdisciplinary team made up of physician-geneticists, molecular biologists, geneticists and bioinformatics specialists.

Tests are carried out within 8 weeks


Results of the test along with their description and indications for prophylactics are issued by a physician during the final medical consultation on a date arranged with the patient.

Cost
of genetic tests


Tests are performed for a fee. Prices depend on the type of test (among others, the numbers of analysed genes)
and are available at the Petra Medica Medical Centre helpline: +48 22 740 20 20.

Why should you consider genetic tests?


Genetic testing is a valuable tool in cancer prevention.
These are just a few reasons why it is worth to undergo genetic testing:

  • By learning your genetic burden, you can take actions which are most beneficial in your situation – carry out tests focusing on the detected risk.

  • Cancers detected at an early stage are much more treatable. If you do have a genetic burden and you will indeed develop the disease in the future, by following your doctor’s instructions you will probably have the disease detected at the earliest stage and cured effectively, thus ensuring yourself a longer life and greater comfort.

  • In the case of some types of cancer (e.g. colon cancer), regular prophylactic tests can fully protect you against cancer developing in the first place. By being aware of your genetic burden with regard to specific cancers, you can learn that you should have certain screening tests carried out earlier or more frequently than the average population.

  • By enhancing the preventive measures, you become more responsible not only for yourself, but also your loved ones, in particular your children. Children of parents undergoing cancer treatment are the ones most prone to require special care.

  • Knowing that a cancer is hereditary might impact the therapy selected by your doctors.

  • The test identifies all known genetic variants related to incidence of hereditary cancers. If your family has a history of cancer, it is worth learning whether you also have an increased risk of developing the disease, thus reducing the fear of cancer.


Scope of the genetic testing service


Regardless of the genetic test selected, the genetic testing service includes:

Stages of the genetic test




Types of genetic tests for cancer risk

Knowing about your genetic burden allows you to take effective preventive measures. In order to detect irregularities, the doctor will provide the patient with comprehensive recommendations and guidance with regard to preventive tests: how, when and how frequently should the patient monitor his or her health condition in order to detect cancer in the earliest stage possible.

Type of genetic testAnalysed genes:
A comprehensive test: it includes all genes which, if mutated, increase the risk of developing cancerAKT1, APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CYP21A2, EPCAM, EXO1, FANCC, FH, FLCN, GALNT12, GDNF, GREM1, HNF1A, HNF1B, KIF1B, MAX, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PIK3CA, PMS1, PMS2, POLD1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD51, RAD51C, RAD51D, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, STK11, TGFBR2, TMEM127, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3
Endometrial (uterine) cancer EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN
Colon cancerAKT1, APC, ATM, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, EXO1, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH6, MUTYH, PIK3CA, PMS1, PMS2, POLD1, PTEN, SMAD4, STK11, TGFBR2, TP53
Prostate cancerBRCA1, BRCA2, CHEK2, NBN, TP53
Pancreatic cancerAPC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, SMAD4, STK11, TP53
Stomach cancerBMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2, SMAD4
Gastrointestinal stromal tumours (GIST), paraganglioma and phaeochromocytomaGDNF, KIF1B, MAX, MEN1, NF1, PRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, TP53, VHL
Skin cancerCDKN2A, CDK4, MC1R, MITF, PTEN, PTCH1, RB1, TP53, XRCC3
Thyroid cancerAPC, MEN1, PTEN, RET, TP53
Renal cancerEPCAM, FH, FLCN, HNF1A, HNF1B, MET, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN, SDHB, SDHD, TSC1, TSC2, VHL, WT1
Breast and ovarian cancerATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FANCC, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51, RAD51C, RAD51D, STK11, TP53, XRCC2, XRCC3


How do I determine the risk of developing a specific type of cancer?

Around 25% of cancer cases are caused by congenital mutations in the genes. Nowadays, many links between specific genetic mutations and the actual risk of developing cancer have been detected. A test makes it possible to determine whether a given person has specific mutations which increase the risk of developing the disease. If such mutations are detected, the doctor provides the person with recommendations for prophylactic tests to ensure that if the disease does develop, effective treatment is initiated at an early stage of the disease.

What types of cancer can be detected?

Who are such tests intended for?

Everyone can have such tests performed, however, they are particularly directed at individuals, who:

• have a family history of cancer,
• experience symptoms or have a feeling that they are carriers of disease-causing genetic mutations,
• are aged between 18 and 55,
• wish to develop optimal cancer prevention scenarios tailored to their needs.

What method is used for genetic testing?

The tests are performed with next-generation sequencing (NGS). The scientific solutions and methods used allow for precise determination of the genetic burden which can lead to developing cancer. We test between a few and up to over 60 separate genes which, if mutated, increase the statistical risk of specific cancers (see the test panel list).

How is the test material collected?

Test material collection is one of the elements of the service. A small amount of blood (up to 10 ml) is sufficient to perform a test. Blood is collected in a treatment room at the Petra Medica Medical Centre.

Where can I have the test performed?

Genetic tests can be carried out in the Petra Medica Medical Centre at Mlądzka 27 St in Warsaw. This is also the address where specialist consultations – the initial, qualifying consultation and the final consultation during which results are issued – are carried out. More information is available at the following phone number: 22 740 20 20.

How should I prepare for the test?

You do not need to make any special preparations for blood sampling. The sample can be collected directly after the qualification consultation. In order to get ready for the medical consultation, you should read the genetic interview questions which will be asked during the consultation. Click here to download the questionnaire.

How long will I wait for the test results?

The test result is available within maximally 8 weeks. Our customer service team will inform you when the test results are ready by calling to book the final consultation.

How much do genetic tests cost?

The price depends on the test type (i.a. the number of genes to be analysed). Details are available at the Petra Medica Medical Centre helpline: + 48 22 740 20 20.

What does the genetic testing service include?

Regardless of the genetic test selected, the genetic testing service includes:
• in-depth medical consultation qualifying for tests (selecting the optimal scope of the test based on an interview),
• collection of genetic material (blood) for analysis,
• performance of sensitive and accurate genetic tests (profiled or comprehensive tests),
• preparation of the description and interpretation of test results along with individual indications for the patient with regard to disease prevention and health monitoring,
• final consultation with the physician-geneticist in order to discuss and issue the test results,
• reinterpretation of results within 12 months after the test was performed (possible update of the result description in relation to the latest discoveries of global science),
•coordination of the test performance process by the nursing and customer service staff – including booking necessary tests and visits in partner medical facilities, as recommended by the doctor.

Do genetic tests need to be repeated?

No. Genetic tests in the scope of the selected gene panel are carried out once in a lifetime, as the material we test is not subject to change after birth. However, we recommend preparing an update of the result description or reinterpretation of results once a 12-24 months.

What assistance can I count on when taking a test?

Test results are issued by your doctor. During that consultation the doctor guides the patient – depending on the test results – towards specific preventive measures. After the lapse of 12-24 months from the date on which the test was performed, as part of oncological supervision we offer a reinterpretation of results in relation to the latest discoveries of global science (connecting detected mutations with newly discovered disease entities).
Reinterpretation of results will take into account the latest scientific and medical data which might provide the patient with new or more detailed indications for preventive measures.

What does a description of test results include?

A description of test results lists the patient's disease-causing genetic mutations (if any were identified). An essential complement to the description are detailed recommendations for cancer prevention, tailored to the needs of the individual patient and prepared by an interdisciplinary team of doctors and researchers.

PETRA MEDICA Sp z o.o. was established in 2005 as a continuation of the “Centrum”Medical Centre, which had been active on the medical market since 1996. The Petra Medica Medical Centre offers medical services for the most demanding clients. A careful selection of medical staff, comfortable furnishings, special apparatus and equipment, advanced technologies and management system allow us to offer our patients services meeting the highest standards.

The range of services includes, inter alia, primary health care, secondary care consultations, diagnostic tests, occupational medicine, outpatient services and nursing care, home visits, medical assistance at night and during holidays. Petra Medica Medical Rescue carries out transport services for patients in Poland and abroad, offers specialised ambulances, medical support during sporting events and first-aid training courses. In July 2015 Petra Medica Sp. z o.o. started medical coverage of foreigners applying for refugee status in Poland.

We offer comprehensive medical services in our own facilities in Warsaw and through more than 30 partner facilities. The Petra Medica Medical Centre offers services to institutional customers and individual patients (on a commercial basis, as part of cooperation with insurance companies and under contracts concluded with the National Health Fund).



Petra Medica Sp. z o.o.

Centrum Medyczne PETRA MEDICA Branch 1
ul. Mlądzka 27, 04-136 Warszawa

To make an appointment, call: 22 740 20 20

Partner: Warsaw Genomics 

ul. Żwirki i Wigury 93
02-089 Warszawa